EGFR and non-small cell lung carcinoma: The prevalence of these mutations in NSCLC is 10% and can be classified as ESCAT IIB. Prospective, nonrandomized studies have shown benefit in at least PFS when patients with rare EGFR mutations were treated with osimertinib and afatinib [26,30-32].